• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Amphastar Pharmaceuticals Inc. (Amendment)

    2/9/23 11:07:31 AM ET
    $AMPH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AMPH alert in real time by email
    SC 13G/A 1 tv0255-amphastarpharmaceutic.htm SCHEDULE 13G/A amphastarpharmaceuticalsinc

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G

    Under the Securities Exchange Act of 1934
    (Amendment No.: 3)*

    Name of issuer:  Amphastar Pharmaceuticals Inc.

    Title of Class of Securities:  Common Stock

    CUSIP Number:  03209R103

    Date of Event Which Requires Filing of this Statement: December 30, 2022

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    (Continued on the following page(s))

     

     

    13G

    CUSIP No.:  03209R103

    1.  NAME OF REPORTING PERSON
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

    The Vanguard Group - 23-1945930

    2.  CHECK THE APPROPRIATE [LINE] IF A MEMBER OF A GROUP

    A. 

    B.  X

    3.  SEC USE ONLY

    4.  CITIZENSHIP OF PLACE OF ORGANIZATION

    Pennsylvania

    (For questions 5-8, report the number of shares beneficially owned by each reporting person with:)

    5.  SOLE VOTING POWER

    0

    6.  SHARED VOTING POWER

    65,941

    7.  SOLE DISPOSITIVE POWER

    2,524,028

    8.  SHARED DISPOSITIVE POWER

    97,779

    9.  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    2,621,807

    10.  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    N/A

    11.  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    5.42%

    12.  TYPE OF REPORTING PERSON

    IA

     

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G
    Under the Securities Act of 1934

    Item 1(a) - Name of Issuer:

    Amphastar Pharmaceuticals Inc.

    Item 1(b) - Address of Issuer's Principal Executive Offices:

    11570 6th Street
    Rancho Cucamonga, CA 91730

    Item 2(a) - Name of Person Filing:

    The Vanguard Group - 23-1945930

    Item 2(b) – Address of Principal Business Office or, if none, residence:

    100 Vanguard Blvd.
    Malvern, PA 19355

    Item 2(c) – Citizenship:

    Pennsylvania

    Item 2(d) - Title of Class of Securities:

    Common Stock

    Item 2(e) - CUSIP Number

    03209R103

    Item 3 - Type of Filing:

    This statement is being filed pursuant to Rule 13d-1.  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

    Item 4 - Ownership:

      (a) Amount Beneficially Owned:

      (b) Percent of Class:

     

     

    (c)  Number of shares as to which such person has:

    (i)  sole power to vote or direct to vote:  

    (ii)  shared power to vote or direct to vote:  

    (iii)  sole power to dispose of or to direct the disposition of:  

    (iv)  shared power to dispose or to direct the disposition of:  

    Comments:

    The responses to questions 5 through 9 and 11 on the cover page(s) are incorporated by reference into this Item 4.  

    Item 5 - Ownership of Five Percent or Less of a Class:

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐

    Item 6 - Ownership of More Than Five Percent on Behalf of Another Person:

    The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein.

    No one other person's interest in the securities reported herein is more than 5%.

    Item 7 - Identification and Classification of the Subsidiary Which Acquired The Security Being Reported on by the Parent Holding Company:

    Not applicable

    Item 8 - Identification and Classification of Members of Group:

    Not applicable

    Item 9 - Notice of Dissolution of Group:

    Not applicable

    Item 10 - Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date:  February 9, 2023

    By /s/ Ashley Grim
    Name: Ashley Grim
    Title:  Head of Global Fund Administration

    Get the next $AMPH alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AMPH

    DatePrice TargetRatingAnalyst
    5/12/2025$30.00Overweight → Neutral
    Analyst
    2/4/2025$66.00 → $36.00Overweight → Neutral
    Piper Sandler
    11/22/2024$55.00Equal Weight
    Wells Fargo
    3/5/2024$60.00Overweight
    JP Morgan
    11/17/2023$63.00Neutral
    BofA Securities
    7/25/2023$70.00Buy
    Jefferies
    10/21/2022$36.00Buy
    Jefferies
    7/29/2022$44.00Overweight
    CapitalOne
    More analyst ratings

    $AMPH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CEO & CHIEF SCIENTIFIC OFFICER Zhang Jack Y. exercised 200,000 shares at a strike of $13.03, increasing direct ownership by 8% to 2,847,659 units (SEC Form 4)

      4 - Amphastar Pharmaceuticals, Inc. (0001297184) (Issuer)

      6/16/25 5:19:35 PM ET
      $AMPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Lee Howard was granted 5,122 shares and covered exercise/tax liability with 923 shares, increasing direct ownership by 3% to 151,976 units (SEC Form 4)

      4 - Amphastar Pharmaceuticals, Inc. (0001297184) (Issuer)

      6/4/25 8:04:41 PM ET
      $AMPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Deflin Gayle was granted 5,122 shares, increasing direct ownership by 88% to 10,914 units (SEC Form 4)

      4 - Amphastar Pharmaceuticals, Inc. (0001297184) (Issuer)

      6/4/25 7:45:15 PM ET
      $AMPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AMPH
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Amphastar Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

      RANCHO CUCAMONGA, CA / ACCESSWIRE / January 8, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Jack Zhang, CEO and President, and Bill Peters, CFO will be presenting at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15th, 2025, at 11:15 am PST. For access, visit Amphastar's Pharmaceuticals website at http://ir.amphastar.com. This webcast will be available for 30 days following the presentation.About Amphastar:Amphastar is a biopharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically-challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the Comp

      1/8/25 6:00:00 AM ET
      $AMPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amphastar Pharmaceuticals to Present at the 36th Annual Piper Sandler Healthcare Conference

      RANCHO CUCAMONGA, CA / ACCESSWIRE / November 26, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO, and Dan Dischner SVP of Corp. Communication, will participate in an Analyst-Moderated fireside chat at the 36th Annual Piper Sandler Healthcare Conference on Wednesday, December 4th, 2024 at 11:30 am EST. For access, visit Amphastar's Pharmaceuticals website at http://ir.amphastar.com. This webcast will be available for 30 days following the presentation.About Amphastar:Amphastar is a biopharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically-challenging generic and proprietary injectable, inhalatio

      11/26/24 4:05:00 PM ET
      $AMPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amphastar Pharmaceuticals to Present at the Jefferies London Healthcare Conference

      RANCHO CUCAMONGA, CA / ACCESSWIRE / November 13, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO, and Jacob Liawatidewi, EVP of Corporate Administration, will participate in an Analyst-Moderated fireside chat at the Jefferies London Healthcare Conference on Wednesday, November 20, 2024 at 3:30 pm GMT. For access, visit Amphastar's Pharmaceuticals website at http://ir.amphastar.com. This webcast will be available for 30 days following the presentation.About Amphastar:Amphastar is a biopharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically-challenging generic and proprietary injectable, inhalatio

      11/13/24 4:05:00 PM ET
      $AMPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AMPH
    SEC Filings

    See more
    • Amphastar Pharmaceuticals Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - Amphastar Pharmaceuticals, Inc. (0001297184) (Filer)

      6/3/25 8:46:19 PM ET
      $AMPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Amphastar Pharmaceuticals Inc.

      10-Q - Amphastar Pharmaceuticals, Inc. (0001297184) (Filer)

      5/8/25 4:24:18 PM ET
      $AMPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amphastar Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Amphastar Pharmaceuticals, Inc. (0001297184) (Filer)

      5/7/25 4:23:10 PM ET
      $AMPH
      Biotechnology: Pharmaceutical Preparations
      Health Care